NanoViricides Accounts Payable

NanoViricides (NNVC) currently reports a accounts payable of $130B as of March 2026. That compares with $350K in the prior-year period — up 38226691.2% year over year. Use the charts on this page to explore NanoViricides's accounts payable history and peer comparisons.

NanoViricides's accounts payable increased from $350K to $130B — a 38226691.2% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

NanoViricides reported $130B in accounts payable as of March 2026. That compares with $350K in the prior-year period — up 38226691.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $130B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for NanoViricides, and consider following NNVC for alerts when major investors trade the stock.

NanoViricides is classified in the Healthcare sector. On accounts payable, it currently shows $130B. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NNVC with unrelated industries.